HEME OXYGENASE-1 HAS AN ANTITUMOR ROLE IN BREAST CANCER

GANDINI NA; ALONSO EN; FERMENTO ME; MASCARÓ M; ABBA MC; COLO GP; AREVALO J; FERRONATO MJ; GUEVARA JA; NUÑEZ M; PICHEL P; CURINO AC; FACCHINETTI MM

ANTIOXIDANTS & REDOX SIGNALING

MARY ANN LIEBERT INC

Lugar: New York; Año: 2019 vol. 30 p. 2030 - 2049

1523-0864

Aims: Heme Oxygenase-1 (HO-1) is an enzyme involved in cellular responses to oxidative stress and has also been shown to regulate processes related to cancer progression. In this regard, HO-1 has been shown to display a dual effect with either antitumor or protumor activity, being this also true for breast cancer (BC). In this work we intended to address this discrepancy regarding the role of HO-1 in BC.Results: HO-1 was detected in human breast cancer tissues, and its protein levels correlated with reduced tumor size and longer overall survival time of patients, thus suggesting the clinical importance of HO-1 in this type of cancer. Contrariwise, nuclear localization of HO-1 correlated with higher tumor grade suggesting that the effect of HO-1 is dependent on its cellular localization. In vivo experiments showed that both pharmacological activation and genetic overexpression of HO-1 reduce the tumor burden in two different animal models of BC. Furthermore, the pharmacological and genetic activation of HO-1 in several BC cell lines both reduce the cellular viability by inducing apoptosis and cell cycle arrest and decrease the cellular migration and invasion rates by modulating pathways involved in the epithelial-mesenchymal transition. Furthermore, HO-1 activation impaired in vivo the metastatic dissemination.Innovation and conclusions: by using various BC cell lines and animal models as well as human tumor samples we demonstrated that total HO-1 displays antitumor activities in BC. Furthermore, our studies suggest that HO-1 subcellular localization may explain the differential effects observed for the protein in different tumor types.